High Expression of S100P is Associated with Unfavorable Prognosis and Tumor Progression in Patients with Epithelial Ovarian Cancer

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2015 Sep 24

PMID 26396916

Citations 15

Authors

Xiangyu Wang

Tian Tian

Xukun Li

Meng Zhao

Yanhui Lou

Jingfeng Qian

Zhihua Liu

Hongyan Chen

Zhumei Cui

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence has demonstrated that S100P is involved in the tumorigenesis and progression of multiple cancers. In the current study, we evaluated the expression of S100P in epithelial ovarian cancer and assessed its relevance to clinicopathological characteristics. Moreover, we investigated the biological effects of S100P using A2780 and SKOV3 cells. S100P expression was significantly increased in epithelial ovarian cancer specimens compared with fallopian tube tissues and normal ovary tissues. And high expression of S100P in epithelial ovarian cancer samples was significantly associated with tumor stage (P<0.001), serum CA125 level (P=0.026), residual tumor (P<0.001), ascites (P<0.001) and lymph nodes metastasis (P<0.001). Multivariate Cox analysis showed that S100P expression was an independent prognostic factor of overall survival (OS) and progression free survival (PFS) (P=0.017 and 0.031, respectively). Functional assays showed that overexpression of S100P promoted cell proliferation and cell cycle progression but did not affect cell migration and invasion in A2780 and SKOV3 cells. These data suggest that S100P may contribute to tumor development in epithelial ovarian cancer and could be a useful marker for the prognosis of epithelial ovarian cancer patients.

Citing Articles

Advances in S100 protein family for gynecological malignancies.

Wu S, Xu J Discov Oncol. 2025; 16(1):287.

PMID: 40057924 PMC: 11891126. DOI: 10.1007/s12672-025-02028-x.

overexpression stimulates cell proliferation and is predictive of poor outcome in ovarian cancer.

Jin W, Hui H, Jiang J, Li B, Deng Z, Tuo X Transl Cancer Res. 2024; 13(10):5265-5277.

PMID: 39525021 PMC: 11543041. DOI: 10.21037/tcr-24-430.

Solanum nigrum Linn.: Advances in anti-cancer activity and mechanism in digestive system tumors.

Pei H, Yang J, Li W, Luo X, Xu Y, Sun X Med Oncol. 2023; 40(11):311.

PMID: 37775552 DOI: 10.1007/s12032-023-02167-7.

Calcium signals and potential therapy targets in ovarian cancer (Review).

Deng F, Fu M, Zhao C, Lei J, Xu T, Ji B Int J Oncol. 2023; 63(5).

PMID: 37711071 PMC: 10552713. DOI: 10.3892/ijo.2023.5573.

LHPP Inhibits the Viability, Migration, and Proliferation of PDAC Cells and Significantly Affects the Expression of SDC1 and S100p.

Xia Z, Zhao S, Gao X, Sun H, Yang F, Zhu H Technol Cancer Res Treat. 2023; 22:15330338231177807.

PMID: 37321804 PMC: 10278439. DOI: 10.1177/15330338231177807.

References

Whiteman H, Weeks M, Dowen S, Barry S, Timms J, Lemoine N . The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res. 2007; 67(18):8633-42. DOI: 10.1158/0008-5472.CAN-07-0545. View

Guo L, Chen S, Jiang H, Huang J, Jin W, Yao S . The expression of S100P increases and promotes cellular proliferation by increasing nuclear translocation of β-catenin in endometrial cancer. Int J Clin Exp Pathol. 2014; 7(5):2102-12. PMC: 4069912. View

Parkkila S, Pan P, Ward A, Gibadulinova A, Oveckova I, Pastorekova S . The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol. 2008; 8:2. PMC: 2254630. DOI: 10.1186/1472-6890-8-2. View

Fuentes M, Nigavekar S, Arumugam T, Logsdon C, Schmidt A, Park J . RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum. 2007; 50(8):1230-40. DOI: 10.1007/s10350-006-0850-5. View

Levanon K, Crum C, Drapkin R . New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008; 26(32):5284-93. PMC: 2652087. DOI: 10.1200/JCO.2008.18.1107. View

Bartling B, Rehbein G, Schmitt W, Hofmann H, Silber R, Simm A . S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer. 2007; 43(13):1935-43. DOI: 10.1016/j.ejca.2007.06.010. View

Ge F, Wang C, Wang W, Wu B . S100P predicts prognosis and drug resistance in gastric cancer. Int J Biol Markers. 2013; 28(4):e387-92. DOI: 10.5301/jbm.5000034. View

Yin M, Li C, Li X, Lou G, Miao B, Liu X . Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011; 104(1):29-36. DOI: 10.1002/jso.21912. View

Shiota M, Tsunoda T, Song Y, Yokomizo A, Tada Y, Oda Y . Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin. BJU Int. 2010; 107(7):1148-53. DOI: 10.1111/j.1464-410X.2010.09535.x. View

10.

Wang Q, He Z, Gao J, Hu S, Huang M, Liu M . S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro. Cancer Lett. 2008; 272(2):277-84. DOI: 10.1016/j.canlet.2008.07.017. View

11.

Romero I, Bast Jr R . Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012; 153(4):1593-602. PMC: 3320264. DOI: 10.1210/en.2011-2123. View

12.

Kim J, Jung K, Noh J, Eun J, Bae H, Xie H . Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol. 2009; 35(6):1257-64. View

13.

Beer D, Kardia S, Huang C, Giordano T, Levin A, Misek D . Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002; 8(8):816-24. DOI: 10.1038/nm733. View

14.

Chudecka-Glaz A, Cymbaluk-Ploska A, Menkiszak J, Sompolska-Rzechula A, Toloczko-Grabarek A, Rzepka-Gorska I . Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014; 7:62. PMC: 4094548. DOI: 10.1186/1757-2215-7-62. View

15.

Chang X, Monitto C, Demokan S, Kim M, Chang S, Zhong X . Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 2010; 70(7):2870-9. PMC: 2849007. DOI: 10.1158/0008-5472.CAN-09-3427. View

16.

McKiernan E, McDermott E, Evoy D, Crown J, Duffy M . The role of S100 genes in breast cancer progression. Tumour Biol. 2010; 32(3):441-50. DOI: 10.1007/s13277-010-0137-2. View

17.

Kessler M, Fotopoulou C, Meyer T . The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin. Int J Mol Sci. 2013; 14(4):6571-96. PMC: 3645655. DOI: 10.3390/ijms14046571. View

18.

Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R . Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006; 66(2):1199-207. DOI: 10.1158/0008-5472.CAN-05-2605. View

19.

He Z, Gao J, Wang Q, Liu M, Li Y, Li X . S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3. Oncol Rep. 2008; 20(2):325-32. View

20.

Sato N, Hitomi J . S100P expression in human esophageal epithelial cells: Human esophageal epithelial cells sequentially produce different S100 proteins in the process of differentiation. Anat Rec. 2002; 267(1):60-9. DOI: 10.1002/ar.10085. View